June 2011

Drug-Eluting Balloons: Emerging Opportunities in Peripheral Vascular Treatment in Europe

Introduction:

Millennium Research Group’s new Physician Forum study investigates physician perceptions of drug-eluting balloons for use in peripheral vascular treatment. Restenosis is a recurring problem in many patients suffering with peripheral artery disease, even when lesions are treated with drug-eluting stents (DES). The use of a drug, delivered to the target lesion through a stent or balloon is meant to hinder new cell growth and, hence, restenosis within the vessel. The use of DES has become associated with less restenosis but higher rates of thrombosis, which is attributed, for the most part, to the polymer that binds the drug to the DES. This new publication looks at European physician opinions of drug-eluting balloons both from a current user and potential adopter (nonuser) perspective.

Scope:

What Questions Will Physician Forum Help You Answer?

  • Which specialties and what countries are adopting drug-eluting balloons more readily and why?
  • What is the potential for drug-eluting balloons and to what extent will the increasing volume of clinical data impact physicians' use of drug-eluting balloons?
  • What patient/lesion types are most likely to be treated with a drug-eluting balloon?
  • What are the barriers to drug-eluting balloon adoption?
  • Will drug-eluting balloons be used with or without stents, and what does this mean for the future of bare-metal stents (BMS) and DES?
  • What are physician perceptions of and preferences for in terms of currently available drug-eluting balloon brands?

Key Sections: The following is an overview of the structure of the publication. The full publication contains 67 slides.

  • Key Findings
  • Introduction
    • Introduction to Drug-Eluting Balloons
    • Terminology and Scope
  • Commercial Context
    • Commercial Context
  • Methodology
    • Survey Design
    • Specialties Analysis
    • Years in Practice
    • Place of Practice
    • Procedure Volumes
    • Experience of Current Practitioners
  • Analysis of Survey Results
    • Usage Rates
    • Current Practice Patterns and Perceptions of Drug-Eluting Balloons
      • Users
        • Drug-Eluting Balloon Usage, by Artery Type and by Country
        • Drug-Eluting Balloon Usage, by Artery Type and Specialty,
        • Current Drug-Eluting Balloon Penetration by Artery Type and Country
        • Use of Drug-Eluting Balloons with/without a Stent, by Artery Type
        • Use of Drug-Eluting Balloons with DES/BMS/without Stent, by Artery Type
        • Why Physicians use Drug-Eluting Balloon + DES in the Same Procedure
        • Price Premium for a Drug-Eluting Balloon Compared to a DES
        • Price Premium for a Drug-Eluting Balloon Compared to a PTA Balloon
      • Nonusers
        • Theoretical Use of Drug-Eluting Balloon with/without Stent, by Artery Type,
        • Theoretical Use of Drug-Eluting Balloon with DES/BMS/without Stent, by Artery Type
        • Factors Preventing Use of Drug-Eluting Balloons in Peripheral Interventions, by Country
      • Combined Sample
        • Technology Ratings for Treating Peripheral Artery Disease in the Tibial & Peroneal Arteries
        • Technology Ratings for Treating Peripheral Artery Disease in the SFA & Popliteal Arteries
        • Benefits of Using Drug-Eluting Balloons in Lower Limb Procedures
        • Benefits of Using Drug-Eluting Balloons in Lower Limb Procedures, by Specialty
        • Opinions on Paclitaxel use in Drug-Eluting Balloon for Treatment of Peripheral Artery Disease, by Segment and Specialty
        • Opinions on Drug-Eluting Balloon Drug Transfer
        • Opportunities for Drug-Eluting Balloons Compared with Drug-Eluting Bioabsorbable Stents
    • Brand Awareness and Perceptions
      • Familiarity with Drug-Eluting Balloon Products, by Brand
      • Currently Used Drug-Eluting Balloon Products, by Brand and Country
      • Retention Ratio, by Brand
      • Clinical Evidence of Drug-Eluting Balloons for Peripheral Artery Disease, by Brand
      • Efficacy of Drug-Eluting Balloons for Peripheral Artery Disease, by Brand
      • Safety of Drug-Eluting Balloons for Peripheral Artery Disease, by Brand
      • Deliverability of Drug-Eluting Balloons for Peripheral Artery Disease, by Brand
      • Currently Used and Preferred Drug-Eluting Balloon Brands, by Artery Type
      • Overall Impression of Drug-Eluting Balloon Products, by Brand
      • Requirement to Try Drug-Eluting Balloon Products, by Brand
    • Future Practice Patterns
      • Users
        • Change in Drug-Eluting Balloon Usage in the Next 12 Months, by Country
        • Factors Increasing Drug-Eluting Balloon Usage, by Country
        • Current and Anticipated Future Drug-Eluting Balloon Penetration, by Country
        • Current and Anticipated Future Drug-Eluting Balloon Penetration, by Artery
      • Nonusers
        • Intention to Adopt Drug-Eluting Balloons, by Country
        • Factors Increasing Drug-Eluting Balloon Usage, by Country
        • Respondents Unwilling to Adopt Drug-Eluting Balloons for Peripheral Interventions in Next 12 Months, by Specialty and Country
        • Current and Anticipated Future Drug-Eluting Balloon Penetration, by Country
        • Current and Anticipated Future Drug-Eluting Balloon Penetration, by Artery
      • Combined Sample
        • Factors Resulting in Stable Drug-Eluting Balloon Usage, by Country
        • Factors Increasing Drug-Eluting Balloon Usage, by Segment and Specialty
        • Potential for Drug-Eluting Balloons, by Segment
        • Potential for Drug-Eluting Balloons, by Country
        • Current and Anticipated Future Drug-Eluting Balloon Penetration, by Country

Methodology: This survey was designed by Millennium Research Group analysts with expertise in the peripheral vascular market.

  • The survey was conducted online in May 2011.
  • Respondents were recruited through a third-party recruiting company. Respondents were invited to participate through e-mail, and the survey was administered online.
  • Respondents were controlled for regional distribution and experience level.
  • The study includes two separate surveys of current users and potential adopters of drug-eluting balloons.
  • Current Users (n = 102):
    • Have used a drug-eluting balloon in peripheral revascularization procedures over the past 6 months
    • Composition
      • 10 General Surgeons
      • 46 Interventional Cardiologists
      • 13 Interventional Radiologists
      • 33 Vascular Surgeons
      • 20 France
      • 21 Germany
      • 20 Italy
      • 16 Spain
      • 20 UK
      • 6 Netherlands
  • Nonusers (n = 102):
    • Have not performed a percutaneous transluminal angioplasty with a drug-eluting balloon in the past 6 months
    • Composition
      • 4 General Surgeons
      • 25 Interventional Cardiologists
      • 36 Interventional Radiologists
      • 37 Vascular Surgeons
      • 20 France
      • 20 Germany
      • 20 Italy
      • 12 Spain
      • 20 UK
      • 10 Netherlands

Authors:

Karene Dumoulin

Contact Sales:

Phone: 1-416-364-7776

E-mail: sales@mrg.net



Search Reports

Mentioned in this report:

  • Aachen Resonance
  • B. Braun
  • BIOTRONIK
  • Eurocor
  • Medtronic Invatec
Decision Resources Group brands include: